Top

Published in:

01-08-2010

Quality-of-Life Measurements in Multiethnic Patients with Systemic Lupus Erythematosus: Cross-Cultural Issues

Authors: Sergio M. A. Toloza, Meenakshi Jolly, Graciela S. Alarcón

Published in: Current Rheumatology Reports | Issue 4/2010

Abstract

Although the survival rate for systemic lupus erythematosus (SLE) has improved dramatically during the past 50 years, the quality of life of patients afflicted with this disease remains poor. Currently existent measures of disease activity and damage in SLE do not capture the patient’s perspective and health-related quality of life (HRQoL). Most studies in SLE pertaining to HRQoL are from developed Western societies, with only a few from others. These studies have been conducted predominantly in women and using the Medical Outcomes Survey Short Form 36, a generic HRQoL instrument that has been shown not to be sensitive to change in lupus. Existent lupus-specific HRQoL measures have not yet been used in SLE clinical trials. New HRQoL research tools are currently undergoing validation in different countries, languages, and cultural settings, which may help dissect the underlying role of socioeconomic status and specific disease-related features that impact SLE-related quality of life.

Liang MH, Socher SA, Larson MG, Schur PH: Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989, 32:1107–1118.CrossRefPubMed

Bombardier C, Gladman DD, Urowitz MB, et al.: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992, 35:630–640.CrossRefPubMed

Symmons DP, Coppock JS, Bacon PA, et al.: Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med 1988, 69:927–937.PubMed

Gladman DD, Urowitz MB, Goldsmith CH, et al.: The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997, 40:809–813.CrossRefPubMed

Strand V, Gladman D, Isenberg D, et al.: Endpoints: consensus recommendations from OMERACT IV. Outcome measures in rheumatology. Lupus 2000, 9:322–327.CrossRefPubMed

Siegel JN: Development of an FDA guidance document for clinical trials in SLE. Lupus 1999, 8:581–585.CrossRefPubMed

McHorney CA, Ware JE Jr, Raczek AE: The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993, 31:247–263.CrossRefPubMed

•• Thumboo J, Strand V: Health-related quality of life in patients with systemic lupus erythematosus: an update. Ann Acad Med Singapore 2007, 36:115–122. This is an interesting review of the literature on HRQoL and of the measures on how to improve it in patients with SLE.PubMed

Alarcón GS, McGwin G Jr, Uribe A, et al.: Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA). XVII. Predictors of self-reported health-related quality of life early in the disease course. Arthritis Rheum 2004, 51:465–474.CrossRefPubMed

10.

Gladman DD, Urowitz MB, Ong A, et al.: A comparison of five health status instruments in patients with systemic lupus erythematosus (SLE). Lupus 1996, 5:190–195.CrossRefPubMed

11.

Gladman DD, Urowitz MB, Ong A, et al.: Lack of correlation among the 3 outcomes describing SLE: disease activity, damage and quality of life. Clin Exp Rheumatol 1996, 14:305–308.PubMed

12.

Jolly M: How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses? J Rheumatol 2005, 32:1706–1708.PubMed

13.

Jolly M, Utset TO: Can disease specific measures for systemic lupus erythematosus predict patients health related quality of life? Lupus 2004, 13:924–926.CrossRefPubMed

14.

•• Aggarwal R, Wilke CT, Pickard AS, et al.: Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus. J Rheumatol 2009, 36:1209–1216. The psychometric properties of two preference-based generic HRQoL measures, the EQ-5D and SF-6D, among US patients with SLE were assessed and found to be satisfactory. Measures of disease activity and damage were found to be weakly correlated with HRQoL.CrossRefPubMed

15.

Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol Med 1998, 28:551–558.CrossRef

16.

Milligan SE, Hom DL, Ballou SP, et al.: An assessment of the Health Assessment Questionnaire functional ability index among women with systemic lupus erythematosus. J Rheumatol 1993, 20:972–976.PubMed

17.

Burckhardt CS, Archenholtz B, Bjelle A: Quality of life of women with systemic lupus erythematosus: a comparison with women with rheumatoid arthritis. J Rheumatol 1993, 20:977–981.PubMed

18.

Lash AA: Quality of life in systemic lupus erythematosus. Appl Nurs Res 1998, 11:130–137.CrossRefPubMed

19.

Archenholtz B, Burckhardt CS, Segesten K: Quality of life of women with systemic lupus erythematosus or rheumatoid arthritis: domains of importance and dissatisfaction. Qual Life Res 1999, 8:411–416.CrossRefPubMed

20.

Leong KP, Kong KO, Thong BY, et al.: Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQoL). Rheumatology (Oxford) 2005, 44:1267–1276.CrossRef

21.

• Doward LC, McKenna SP, Whalley D, et al.: The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus. Ann Rheum Dis 2009, 68:196–200. The development and testing of a new instrument to measure QoL (L-QoL) in 93 adult SLE patients from the United Kingdom is described.CrossRefPubMed

22.

• McElhone K, Abbott J, Shelmerdine J, et al.: Development and validation of a disease-specific health-related quality of life measure, the LupusQoL, for adults with systemic lupus erythematosus. Arthritis Rheum 2007, 57:972–979. The development and validation process of a self-report (patient-derived items) lupus-specific measure (LupusQoL) in a predominantly female and Caucasian SLE population from the United Kingdom is described.CrossRefPubMed

23.

•• Jolly M, Pickard AS, Wilke C, et al.: Lupus-specific health outcome measure for US patients: the LupusQoL-US version. Ann Rheum Dis 2010, 69:29–33. The first SLE-specific HRQoL instrument modified and validated for use in an ethnically diverse US population is described. Satisfactory psychometric properties are presented.CrossRefPubMed

24.

• Jolly M, Pickard AS, Fogg L, et al.: US patient derived lupus-specific patient reported outcome measure (Lupus-PRO©): validity and reliability. Arthritis Rheum 2008, 58(9 S):S805. The validity and reliability of the LupusPRO in an ethnically heterogeneous US population are presented.

25.

Yu EB, Shikiar R, Howard K, et al.: Validation of LUP-QOL: a lupus-specific measure of health-related quality of life (HRQL) [abstract 0499]. Ann Rheum Dis 2006, 65(Suppl II).

26.

•• Moorthy LN, Peterson MG, Baratelli M, et al.: Multicenter validation of a new quality of life measure in pediatric lupus. Arthritis Rheum 2007, 57:1165–1173. The development and validation of SMILEY as a brief, easily understood, valid, and reliable pediatric, SLE-specific QoL scale are described.CrossRefPubMed

27.

Moorthy LN, Peterson MG, Baratelli MJ, et al.: Preliminary cross-cultural adaptation of a new pediatric health-related quality of life scale in children with systemic lupus erythematosus: an international effort. Lupus 2010, 19:83–88.CrossRefPubMed

28.

Beaton DE, Bombardier C, Guillemin F, Ferraz MB: Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976) 2000, 25:3186–3191.

29.

•• Colangelo KJ, Pope JE, Peschken C: The minimally important difference for patient reported outcomes in systemic lupus erythematosus including the HAQ-DI, pain, fatigue, and SF-36. J Rheumatol 2009, 36:2231–2237. This was a Canadian study addressing the concept of the minimally important difference in patients with SLE. This minimally important difference may differ bidirectionally depending on the measured outcome (specific values for the MCS and PCS scores of the SF-36 are provided).CrossRefPubMed

30.

Kong KO, Ho HJ, Howe HS, et al.: Cross-cultural adaptation of the Systemic Lupus Erythematosus Quality of Life Questionnaire into Chinese. Arthritis Rheum 2007, 57:980–985.CrossRefPubMed

31.

Jolly M, Pickard AS, Wilke C, et al.: Development and validation of a US lupus specific patient reported outcome measure. Arthritis Rheum 2007, 56(9 S):S113.

32.

Bastian HM, Roseman JM, McGwin G Jr, et al.: Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002, 11:152–160.CrossRefPubMed

33.

• Durán S, Apte M, Alarcón GS; LUMINA Study Group: poverty, not ethnicity, accounts for the differential mortality rates among lupus patients of various ethnic groups. J Natl Med Assoc 2007, 99:1196–1198. This carefully written review emphasizes the role of poor SES (poverty) in the increased mortality rates observed in patients with SLE.PubMed

34.

•• Kuriya B, Gladman DD, Ibañez D, Urowitz MB: Quality of life over time in patients with systemic lupus erythematosus. Arthritis Rheum 2008, 59:181–185. In this study, SF-36 scores changed little over time (during an 8-year period); these changes were not affected by disease activity, glucocorticoid exposure, or accrued damage but were affected by the concomitant presence of fibromyalgia.CrossRefPubMed

35.

Clarke AE, Panopalis P, Petri M, et al.: SLE patients with renal damage incur higher health care costs. Rheumatology (Oxford) 2008, 47:329–333.CrossRef

36.

•• Appenzeller S, Clarke AE, Panopalis P, et al.: The relationship between renal activity and quality of life in systemic lupus erythematosus. J Rheumatol 2009, 36:947–952. SLE patients with active renal disease had a slightly poorer QoL (physical subscales) than those without renal disease; however, it was not possible to accurately estimate whether a longitudinal change in renal disease activity was associated with a change in QoL.CrossRefPubMed

37.

• Mok CC, Ho LY, Cheung MY, et al.: Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study. Scand J Rheumatol 2009, 38:121–127. This study evaluated and demonstrated the effects of persistent active disease and previous and new damage on the deterioration of SF-36 scores.CrossRefPubMed

38.

• Dua A, Kamen DL, Barnado AL, et al.: Variable health-related quality of life among African American cohorts of patients with systemic lupus erythematosus. Arthritis Rheum 2009, 60(10 S):S112. This was a comparative study of demographic and HRQoL variables in two African American SLE patient groups of different genetic admixtures and geographic locations (urban and rural). Significantly worse HRQoL was found among the urban African Americans than among their rural counterparts.

39.

•• Sanchez ML, McGwin G Jr, Durán S, et al.: Factors predictive of overall health over the course of the disease in patients with systemic lupus erythematosus from the LUMINA cohort (LXII): use of the SF-6D. Clin Exp Rheumatol 2009, 27:67–71. The SF-6D utility measure was used in this multiethnic study. Hispanic-Texan ethnicity and higher levels of social support were found to be positive predictors of HRQoL, whereas sociodemographic (older age, poverty) and disease-related (greater disease activity and damage, higher levels of fatigue, helplessness, and abnormal illness-related behaviors) variables were found to be negative predictors; prior SF-6D was found to be the strongest predictor of subsequent HRQoL.PubMed

40.

•• Fernández M, Alarcón GS, McGwin G Jr, et al.: Using the Short Form 6D, as an overall measure of health, to predict damage accrual and mortality in patients with systemic lupus erythematosus: XLVII, results from a multiethnic US cohort. Arthritis Rheum 2007, 57:986–992. In this multiethnic SLE cohort, the SF-6D was found to be associated with damage accrual, but not with mortality. CrossRefPubMed

41.

Freire E, Bruscato A, Ciconelli R: Quality of life in systemic lupus erythematosus patients in northeastern Brazil: is health-related quality of life a predictor of survival for these patients? Acta Reumatol Port 2009, 34:207–211.PubMed

42.

•• Wolfe F, Michaud K, Li T, Katz RS: EQ-5D and SF-36 quality of life measures in systemic lupus erythematosus: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, and fibromyalgia. J Rheumatol 2010, 37:296–304. This was a large comparison study of the EQ-5D and SF-36 (1316 SLE patients vs 13,722 rheumatoid arthritis, 3623 with noninflammatory rheumatic disorders, and 2733 with fibromyalgia). No differences in the EQ-5D and PCS scores among patients with these diseases were found. The MCS of the SF-36 was found to be lower in SLE than in rheumatoid arthritis and noninflammatory rheumatic disorders; poor QoL in SLE was predicted by disease damage and the number of comorbid events.CrossRefPubMed

43.

Khanna S, Pal H, Pandey RM, Handa R: The relationship between disease activity and quality of life in systemic lupus erythematosus. Rheumatology (Oxford) 2004, 43:1536–1540.CrossRef

44.

Klein R, Moghadam-Ki S, LoMonico J, et al.: Quality of life in cutaneous lupus erythematosus. Arthritis Rheum 2009, 60(10 S):S107.

45.

Jolly M, Pickard AS, Mikolaitis R, et al.: Disease activity, body image and health status in Lupus. Arthritis Rheum 2007, 56:S454.

46.

Grootscholten C, Ligtenberg G, Derksen RH, et al.: Health-related quality of life in patients with systemic lupus erythematosus: development and validation of a lupus specific symptom checklist. Qual Life Res 2003, 12:635–644.CrossRefPubMed

47.

•• Grootscholten C, Snoek FJ, Bijl M, et al.: Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/methylprednisolone in a randomized controlled trial. J Rheumatol 2007, 34:1699–1707. This small study compared the treatment effect of cyclophosphamide pulses plus oral prednisone versus azathioprine combined with intravenous methylprednisolone during a 24-month period on HRQoL in 87 predominantly Caucasian patients with proliferative LN. The study showed that aggressive treatment with immunosuppressive drugs and concomitant glucocorticoids improves HRQoL, especially in the first year.PubMed

48.

•• Dussán KB, Magder L, Brodsky RA, et al.: High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures. Lupus 2008, 17:1079–1085. In this small randomized controlled trial, high-dose cyclophosphamide was compared with monthly intravenous cyclophosphamide in first-time cyclophosphamide users. Improvement in several components of the SF-36 was demonstrated at 6 months in the high-dose cyclophosphamide patient group, but equal improvement in the two arms was demonstrated at 36 months.CrossRefPubMed

49.

Medeiros MM, Menezes AP, Silveira VA, et al.: Health-related quality of life in patients with systemic lupus erythematosus and its relationship with cyclophosphamide pulse therapy. Eur J Intern Med 2008, 19:122–128.CrossRefPubMed

50.

Uppal SS, Hayat SJ, Raghupathy R: Efficacy and safety of infliximab in active SLE: a pilot study. Lupus 2009, 18:690–697.CrossRefPubMed

51.

•• Jolly M, Sandler D, Sequeira W, et al.: Hydroxy-chloroquine use and disease specific health related quality of life in systemic lupus erythematosus. Arthritis Rheum 2009, 60(10 S):S108. The beneficial effects of hydroxychloroquine in preventing major lupus flares, retarding damage accrual, and improving patient survival are well-known; however, no demonstrable effect of hydroxychloroquine on the LupusQoL-US or the LupusPRO could be demonstrated in this study.

52.

Alarcón GS, McGwin G, Bertoli AM, et al.: Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort. Ann Rheum Dis 2007, 66:1168–1172.CrossRefPubMed

53.

Ito H, Matsuno T, Hirayama T, et al.: Health-related quality of life in patients with systemic lupus erythematosus after medium to long-term follow-up of hip arthroplasty. Lupus 2007, 16:318–323.CrossRefPubMed

54.

Alvarez-Nemegyei J, Bautista-Botello A, Dávila-Velázquez J: Association of complementary or alternative medicine use with quality of life, functional status or cumulated damage in chronic rheumatic diseases. Clin Rheumatol 2009, 28:547–551.CrossRefPubMed

55.

Karlson EW, Liang MH, Eaton H, et al.: A randomized clinical trial of a psychoeducational intervention to improve outcomes in systemic lupus erythematosus. Arthritis Rheum 2004, 50:1832–1841.CrossRefPubMed

Title: Quality-of-Life Measurements in Multiethnic Patients with Systemic Lupus Erythematosus: Cross-Cultural Issues
Authors: Sergio M. A. Toloza
Meenakshi Jolly
Graciela S. Alarcón
Publication date: 01-08-2010
Publisher: Current Science Inc.
Published in: Current Rheumatology Reports / Issue 4/2010
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-010-0110-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Quality-of-Life Measurements in Multiethnic Patients with Systemic Lupus Erythematosus: Cross-Cultural Issues

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

Quality-of-Life Measurements Versus Disease Activity in Systemic Lupus Erythematosus

Managing Comorbid Disease in Patients with Psoriatic Arthritis

Psoriatic Arthritis: Pharmacotherapy Update

Pitfalls and Opportunities in Measuring Patient Outcomes in Lupus

Application of the GRAPPA Psoriatic Arthritis Treatment Recommendations in Clinical Practice

Vitamin D and Systemic Lupus Erythematosus: Bones, Muscles, and Joints

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page